Two days workshop on Foundation for Leadership and Professional Communication
https://thehimalayantimes.com/kathmandu/biotechnology-society-of-nepal-organises-leadership-workshop/KATHMANDU: Foundations of Leadership and Professional Communication, a two-day workshop organised by the Biotechnology Society of Nepal (BSN) has concluded on Saturday. BSN, the organisation working for promotion of biotechnology in Nepal and abroad, organised the function with the aim of developing professional communication skills among scientific personnel. Welcoming the
New Open Data Innovation Fund for Nepal - apply now!
Do you have innovative ideas on how data can be opened and harnessed to solve Nepal’s development issues? Are you looking for funding to transform your ideas into reality? Then look no further! We are delighted to share that a new Innovation Fund on open data has been launched today – a first for Nepal. This fund – The Open Data Innovation Fund - will help Nepal’s development innovators to address development challenges by suppor
Two Days Proposal Writing Training
Students, Researchers, Academics and Teachers from different faculties convened at Asian Institute of Technology and Management (AITM) to attend the ‘Proposal Writing Workshop’ organized by Biotechnology Society of Nepal (BSN). The workshop was held on 14th and 15th September with an attendance of around 70 participants. The workshop was instructed by Mr. Karl Brown, an Entrepreneur and Skills Development Adviser from National Youth Federation Nepal (NYFN), who was a very ener
AuthorAid's 5th MOOC on "Research Communcation"
AuthorAID offers free online courses in research writing and proposal writing for researchers in developing countries. Our courses are hosted on INASP Moodle. Enrolment is open for our next course starting on 3 October 2017.
CAR T Cells: Genetic Engineering Patients’ Immune Cells to Treat Their Cancers
For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last two decades, targeted therapies like imatinib (Gleevec®) and trastuzumab (Herceptin®)—drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells—have also cemented themselves as standard treatments for many cancers. But over the past several years, immuno